Command Palette

Search for a command to run...

SANOFICONR

4615-0.95%
Market Cap
₹0.00 Cr
Stock P/E
0.00
ROCE
0.00%
ROE
0.00%
Book Value
₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Laggard

Sanofi Consumer Healthcare India Ltd. is lagging significantly behind its peers in key financial metrics including profitability, efficiency, and growth. With no revenue growth or profitability indicators, it is classified as financially weak, while its peers exhibit stronger financial health and growth potential.

Key Points
  • Sanofi shows no revenue growth, EPS, or profitability indicators.
  • Sun Pharma and Cipla are standout performers in terms of growth and returns.
  • Sanofi's high PE ratio indicates it may be overvalued given its lack of performance.
Top Performers
Cipla Ltd.

Strong revenue growth (13.28% YoY) and attractive PE ratio (23.73) with solid profitability metrics.

Sun Pharmaceutical Industries Ltd.

Highest EPS (45.55), strong revenue growth (8.42% YoY), and robust ROE (16.13%).

Dr. Reddy's Laboratories Ltd.

Solid profitability metrics with high ROE (21.76%) and revenue growth (16.54% YoY).

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.